Maccura BiotechnologyLtd Past Earnings Performance
Past criteria checks 1/6
Maccura BiotechnologyLtd's earnings have been declining at an average annual rate of -6.4%, while the Life Sciences industry saw earnings growing at 19.5% annually. Revenues have been declining at an average rate of 1.5% per year. Maccura BiotechnologyLtd's return on equity is 5%, and it has net margins of 12.2%.
Key information
-6.4%
Earnings growth rate
-8.3%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | -1.5% |
Return on equity | 5.0% |
Net Margin | 12.2% |
Next Earnings Update | 23 Oct 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Maccura BiotechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 2,794 | 340 | 845 | 340 |
31 Mar 24 | 2,836 | 316 | 840 | 325 |
31 Dec 23 | 2,896 | 313 | 844 | 324 |
30 Sep 23 | 3,005 | 376 | 801 | 324 |
30 Jun 23 | 3,207 | 477 | 788 | 297 |
31 Mar 23 | 3,360 | 623 | 764 | 285 |
01 Jan 23 | 3,608 | 708 | 786 | 273 |
30 Sep 22 | 3,690 | 761 | 782 | 225 |
30 Jun 22 | 3,802 | 831 | 791 | 224 |
31 Mar 22 | 3,836 | 845 | 758 | 214 |
01 Jan 22 | 3,981 | 957 | 764 | 207 |
30 Sep 21 | 4,184 | 1,024 | 734 | 258 |
30 Jun 21 | 4,212 | 1,015 | 708 | 234 |
31 Mar 21 | 4,255 | 1,032 | 735 | 217 |
31 Dec 20 | 3,704 | 794 | 657 | 202 |
30 Sep 20 | 3,405 | 677 | 648 | 157 |
30 Jun 20 | 3,158 | 565 | 652 | 150 |
31 Mar 20 | 3,019 | 482 | 665 | 143 |
31 Dec 19 | 3,223 | 525 | 723 | 140 |
30 Sep 19 | 3,078 | 504 | 725 | 113 |
30 Jun 19 | 2,956 | 483 | 684 | 113 |
31 Mar 19 | 2,889 | 463 | 668 | 110 |
31 Dec 18 | 2,685 | 445 | 605 | 109 |
30 Sep 18 | 2,568 | 431 | 592 | 113 |
30 Jun 18 | 2,373 | 413 | 496 | 129 |
31 Mar 18 | 2,126 | 394 | 460 | 108 |
31 Dec 17 | 1,970 | 374 | 441 | 88 |
30 Sep 17 | 1,798 | 365 | 410 | 46 |
30 Jun 17 | 1,663 | 340 | 442 | 0 |
31 Mar 17 | 1,570 | 324 | 431 | 0 |
31 Dec 16 | 1,489 | 312 | 414 | 0 |
30 Sep 16 | 1,364 | 303 | 373 | 0 |
30 Jun 16 | 1,220 | 279 | 347 | 0 |
31 Mar 16 | 1,139 | 271 | 314 | 0 |
31 Dec 15 | 1,065 | 251 | 292 | 0 |
30 Sep 15 | 1,024 | 244 | 271 | 0 |
30 Jun 15 | 997 | 243 | 257 | 0 |
31 Mar 15 | 959 | 231 | 244 | 0 |
31 Dec 14 | 935 | 226 | 242 | 0 |
31 Dec 13 | 779 | 193 | 175 | 0 |
Quality Earnings: 300463 has high quality earnings.
Growing Profit Margin: 300463's current net profit margins (12.2%) are lower than last year (14.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300463's earnings have declined by 6.4% per year over the past 5 years.
Accelerating Growth: 300463's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300463 had negative earnings growth (-28.9%) over the past year, making it difficult to compare to the Life Sciences industry average (-7.5%).
Return on Equity
High ROE: 300463's Return on Equity (5%) is considered low.